Search Results for site

Oncofertility National Science Education Network (ONSEN) Dr. Teresa Woodruff initiated the Oncofertility National Science Education Network (ONSEN) in an effort to help attract, prepare and retain female high school students in science majors and careers. ONSEN features educational programs in oncofertility that have been developed…

Introdução Muitos homens que foram diagnosticados com uma doença oncológica consideram a preservação da fertilidade importante e gostariam de ter mais informação sobre as técnicas existentes. No entanto, podem –       Não se sentir confortáveis para abordarem aspetos relacionados com a fertilidade. –       Não ter consciência…

Introdução Muitos homens que foram diagnosticados com uma doença oncológica consideram a preservação da fertilidade importante e gostariam de ter mais informação sobre as técnicas existentes. No entanto, podem –       Não se sentir confortáveis para abordarem aspetos relacionados com a fertilidade. –       Não ter consciência…

Introdução Muitas mulheres que foram diagnosticadas com uma doença oncológica consideram a preservação da fertilidade importante e gostariam de ter mais informação sobre as técnicas existentes. No entanto, podem –       Não se sentir confortáveis para abordarem aspetos relacionados com a fertilidade. –       Não ter consciência…

Research and Translational Medicine: Meeting the Needs of Cancer Patients and Survivors November 14-16, 2017 Prentice Women’s Hospital 250 E. Superior St., Third Floor Chicago, IL 60611 Tuesday, November 14, 2017 Day 1 Education Sessions Registration and Continental Breakfast (8:30 – 9:00am) Fellow Education (9:00am –…

Founder of Oncofertility Consortium: Teresa K. Woodruff, PhD Director of Oncofertility Consortium: Mahmoud Salama MD, PhD Chairs of Scientific Committees of Oncofertility Consortium: Pediatric and Adolescent Committee (PAC): Lillian R. Meacham, MD Female Oncofertility: Leslie Appiah, MD Male Oncofertility: Kyle Orwig,

As the field of oncofertility continues to advance, the Oncofertility Consortium seeks to support various high-risk, high-gain initiatives in order to facilitate the launch of early-stage ideas into future grant-funded projects. Applications for pilot projects are evaluated each year, with only a few awarded with…

Considerations should also be made for young women who are pregnant at the time of cancer diagnosis to achieve a healthy pregnancy. By 2002, the incidence of pregnancy-associated breast cancer had increased to 37.4 per 100,000 deliveries, up from 16.0 in 19631. The co-existence of…

What do patients want to know? Fertility is of great importance to many people diagnosed with cancer 76% of childless reproductive-aged cancer survivors state that they would like to have children in the future1. Many men report that sperm cryopreservation prior to chemotherapy helped them…

Who are appropriate candidates? Ovarian tissue cryopreservation is usually only considered in certain cases: Patients who do not have time to undergo controlled ovarian stimulation (COS) for embryo or oocyte cryopreservation.  COS is the more mature technology and should be the first-line treatment if time allows. Patients…

In general, for women with cancer, controlled ovarian stimulation (COS) for embryo or oocyte cryopreservation is similar to IVF for infertile couples. However, there are some additonal considerations in this population: What is the general protocol for COS? Pre-cycle considerations Ovarian reserve testing. A study…

The Oncofertility Consortium is committed to ensuring that you, cancer patients and survivors, receive critical information about your reproductive health in a timely manner. To support this, we have produced an online enterprise to you, your parents, and your partners about their reproductive options. SaveMyFertility.org is…

The Oncofertility Consortium (OC) is committed to explore and expand reproductive options for those who face fertility threatening conditions and/or medical treatments.  To this end, the OC has created several resources, available through the OC-Scientific Help Agreement for Research Endeavors or OC-SHAREs program, to help the scientific community…

Introduction The Oncofertility Consortium® works with clinical experts to investigate the efficacy and safety of fertility preservation techniques and pregnancy after cancer. Preserving reproductive options BEFORE and DURING cancer treatments Many current fertility preservation techniques require controlled ovarian stimulation (COS) prior to oocyte or embryo…

Hotels for the Annual Oncofertility Conference This year the Oncofertility Consortium will not have a dedicated hotel block as attendees have found significantly lower rates at area hotels by searching Expedia.com, Hotels.com, Orbitz.com, Priceline.com and other travel websites (search Chicago, IL 60611 or Magnificent Mile).

Annual Oncofertility Symposium Our annual conference is an opportunity for leading researchers and healthcare providers to come together to learn about recent developments and share new ideas. Held in Chicago at the Northwestern University campus, this event is an exicting opportunity for those interested in…

Introduction to Oncofertility (Free Online Course – coursra) (intro video) Oncofertility Consortium-ASRM Online Course for Reproductive Health Providers Introduction to Reproduction (Free Online Course – Coursera) ECHO Training (Enriching Communication Skills for Health Professionals in Oncofertility) Master of Science in Reproductive Science and Medicine (MS-RSM)…

Incidence Ataxia Telangiectasia (A-T) has a frequency of approximately 1 in 40,000 births in the United States[1]. The carrier rate of A-T, which is an autosomal recessive genetic condition, is approximately 2.8% in the United States[2]. Natural History A-T is an inherited genetic condition caused…